Lung Cancer | Specialty

Dr. Hellmann on Tumor Mutational Burden Testing in Patients With Lung Cancer

May 12th 2018

Matthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.

Dr. Kirson Discusses the LUNAR Study in Advanced NSCLC

May 10th 2018

Eilon Kirson, MD, PhD, chief medical officer, Novocure, discusses the LUNAR study in advanced non–small cell lung cancer.

Dr. Paik on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

May 9th 2018

Paul K. Paik, MD, clinical director of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of lorlatinib may alter the landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Bazhenova on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

May 7th 2018

Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).

FDA Grants Frontline Atezolizumab Priority Review for NSCLC

May 7th 2018

The FDA has granted a priority review to a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Dr. Ou on the Use of Crizotinib in Patients With ROS1-Rearranged NSCLC

May 5th 2018

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).

Dr. Patel on Novel Agents for Patients With NSCLC

May 3rd 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses novel agents for the treatment of patients with non–small cell lung cancer (NSCLC).

FDA Approval Sought for Frontline Pembrolizumab Combo in Squamous NSCLC

May 3rd 2018

A supplemental biologics license application has been submitted to the FDA for the use of pembrolizumab in combination with standard chemotherapy as a treatment for patients with metastatic squamous non–small cell lung cancer.

Dr. Shaw Discusses Lorlatinib in Lung Cancer

May 3rd 2018

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses lorlatinib in the treatment of patients with lung cancer.

Dr. Urbanic on the Role of Radiotherapy in Oligometastatic NSCLC

May 1st 2018

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the role of radiotherapy in oligometastatic non–small cell lung cancer (NSCLC).

Dr. Garon on Immunotherapy Combinations in NSCLC

April 30th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

FDA Grants Priority Review for Full Approval of Frontline Pembrolizumab Combo in NSCLC

April 30th 2018

The FDA has granted a priority review to a supplemental biologics license application for frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

Frontline Osimertinib Approaches European Approval for NSCLC

April 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.

Expert Details Immunotherapy Developments in Lung Cancer

April 27th 2018

Charles M. Rudin, MD, PhD, discusses ongoing developments with immunotherapy in patients with non–small cell lung cancer.

Chemotherapy Remains Critical in NSCLC Paradigm

April 26th 2018

Mark G. Kris, MD, discusses the continued significance of chemotherapy in patients with NSCLC in the era of targeted agents and immunotherapy.

Dr. Rudin on Immunotherapy Biomarkers in Lung Cancer

April 25th 2018

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Addressing Limitations in EGFR Exon 20-Mutant NSCLC

April 25th 2018

Personalizing Therapy for EGFR Exon 20-Mutant NSCLC

April 25th 2018

Further Research Investigating Poziotinib in NSCLC

April 25th 2018

Poziotinib Data in EGFR Exon 20-Mutant NSCLC

April 25th 2018